Posted by Michael Wonder on 16 Feb 2021
After a controversial Alzheimer’s drug review, FDA’s Woodcock rejects proposal to ‘firewall’ agency and drug companies
16 February 2021 - In response to criticism, a top FDA official maintained that creating a firewall between agency staff and drug company personnel during the process for reviewing medicines “would cause significant negative repercussions for public health.”
The notion was broached two months ago by the Public Citizen advocacy group shortly after an FDA advisory committee voted nearly unanimously not to recommend a controversial Alzheimer’s drug for approval.
